|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-6-3
|
|
pubmed:abstractText |
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified human oncoprotein that stabilizes the c-Myc (MYC) protein. However, the clinical relevance of CIP2A to human cancers had not been demonstrated, but the mechanism of its regulation and its clinical role in cancer were completely unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Autoantigens,
http://linkedlifedata.com/resource/pubmed/chemical/KIAA1524 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/MYC protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-myc,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:BöckelmanCamillaC,
pubmed-author:EvanGerard IGI,
pubmed-author:HaglundCajC,
pubmed-author:HemmesAnnabritaA,
pubmed-author:JunnilaSiinaS,
pubmed-author:JunttilaMelissa RMR,
pubmed-author:KhannaAnchitA,
pubmed-author:LundinMikaelM,
pubmed-author:MurphyDaniel JDJ,
pubmed-author:RistimäkiAriA,
pubmed-author:WestermarckJukkaJ,
pubmed-author:WikstenJan-PatrikJP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
793-805
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19470954-Adenocarcinoma,
pubmed-meshheading:19470954-Autoantigens,
pubmed-meshheading:19470954-Cell Cycle,
pubmed-meshheading:19470954-Cell Line, Tumor,
pubmed-meshheading:19470954-Cell Proliferation,
pubmed-meshheading:19470954-Down-Regulation,
pubmed-meshheading:19470954-Feedback, Physiological,
pubmed-meshheading:19470954-Finland,
pubmed-meshheading:19470954-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19470954-Humans,
pubmed-meshheading:19470954-Immunoblotting,
pubmed-meshheading:19470954-Immunohistochemistry,
pubmed-meshheading:19470954-Kaplan-Meier Estimate,
pubmed-meshheading:19470954-Membrane Proteins,
pubmed-meshheading:19470954-Predictive Value of Tests,
pubmed-meshheading:19470954-Prognosis,
pubmed-meshheading:19470954-Proto-Oncogene Proteins c-myc,
pubmed-meshheading:19470954-RNA, Messenger,
pubmed-meshheading:19470954-RNA, Small Interfering,
pubmed-meshheading:19470954-Registries,
pubmed-meshheading:19470954-Retrospective Studies,
pubmed-meshheading:19470954-Stomach Neoplasms,
pubmed-meshheading:19470954-Tissue Array Analysis,
pubmed-meshheading:19470954-Tumor Markers, Biological
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
|
|
pubmed:affiliation |
Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
